Repligen (NASDAQ:RGEN) Releases Earnings Results, Beats Estimates By $0.04 EPS

Repligen (NASDAQ:RGEN - Get Free Report) posted its earnings results on Tuesday. The biotechnology company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.04, Zacks reports. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business's revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.28 earnings per share. Repligen updated its FY 2025 guidance to 1.630-1.720 EPS.

Repligen Stock Down 3.7 %

Shares of RGEN traded down $5.25 on Tuesday, hitting $138.38. The company's stock had a trading volume of 938,105 shares, compared to its average volume of 713,839. The firm's fifty day moving average price is $139.66 and its 200-day moving average price is $145.97. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen has a fifty-two week low of $102.97 and a fifty-two week high of $182.52. The firm has a market capitalization of $7.77 billion, a price-to-earnings ratio of -272.35, a P/E/G ratio of 4.54 and a beta of 1.27.

Insiders Place Their Bets

In other news, Director Margaret Pax bought 250 shares of the company's stock in a transaction dated Monday, March 17th. The stock was bought at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the transaction, the director now owns 1,043 shares of the company's stock, valued at $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.20% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have commented on RGEN. TD Cowen began coverage on Repligen in a research report on Monday, February 10th. They set a "buy" rating and a $200.00 target price on the stock. StockNews.com upgraded Repligen from a "sell" rating to a "hold" rating in a report on Monday. Royal Bank of Canada raised their price target on shares of Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a report on Friday, February 21st. Canaccord Genuity Group dropped their target price on Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a report on Wednesday, April 16th. Finally, HC Wainwright restated a "buy" rating and set a $180.00 price objective on shares of Repligen in a report on Friday, February 21st. Seven analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $176.82.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.